Nippon India Pharma Fund
The fund maintains a concentrated bet on large-cap pharma majors, with Sun Pharma, Lupin, and Dr. Reddy's anchoring nearly 29% of assets, while healthcare services add defensive diversification through Apollo and diagnostic plays. The exit of JB Chemicals and increased conviction in Dr. Reddy's signal confidence in established, cash-generative players over mid-cap names, positioning the portfolio for sustained dividend yields rather than growth. At 98.7% equity with minimal cash, the manager shows commitment to sector exposure despite volatile macro conditions.
Portfolio analysis · April 2026
NAV & Returns
| Plan | NAV | 1M | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Regular Growth | ₹542.6506 | +7.86% | — | — | — |
| Regular Growth | ₹542.6506 | +7.86% | +9.10% | +24.10% | +13.65% |
Portfolio Metrics(latest month)
vs Category Peers
Highly DifferentiatedActive Share = ½Σ|wfund − wpeer|, computed using leave-one-out peer portfolio within SEBI category.
Similar Funds in Category
What Changed2026-03-31 → 2026-04-30
| Stock | Weight | |
|---|---|---|
| No new entries this month | ||
Full Holdings
| # | Holding | % to NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited INE044A01036 | 13.85% |
| 2 | Lupin Limited INE326A01037 | 7.95% |
| 3 | Dr. Reddy's Laboratories Limited INE089A01031 | 7.04% |
| 4 | Divi's Laboratories Limited INE361B01024 | 6.61% |
| 5 | Cipla Limited INE059A01026 | 5.47% |
| 6 | Apollo Hospitals Enterprise Limited INE437A01024 | 5.01% |
| 7 | MedPlus Health Services Limited INE804L01022 | 3.78% |
| 8 | Vijaya Diagnostic Centre Limited INE043W01024 | 3.36% |
| 9 | Sai Life Sciences Limited INE570L01029 | 3.27% |
| 10 | Ajanta Pharma Limited INE031B01049 | 3.19% |
| 11 | Max Healthcare Institute Limited INE027H01010 | 3.16% |
| 12 | Mankind Pharma Limited INE634S01028 | 3.04% |
| 13 | Aurobindo Pharma Limited INE406A01037 | 2.83% |
| 14 | GlaxoSmithKline Pharmaceuticals Limited INE159A01016 | 2.55% |
| 15 | IPCA Laboratories Limited INE571A01038 | 2.50% |
| 16 | Abbott India Limited INE358A01014 | 2.26% |
| 17 | Thyrocare Technologies Limited INE594H01019 | 2.11% |
| 18 | Alkem Laboratories Limited INE540L01014 | 2.09% |
| 19 | Dr. Lal Path Labs Limited INE600L01024 | 1.99% |
| 20 | Pfizer Limited INE182A01018 | 1.79% |
Sector Allocation
Top 10 sectors by % to NAV. Excludes derivatives.
Frequently Asked Questions
How many stocks does Nippon India Pharma Fund hold?
Nippon India Pharma Fund holds 34 stocks as per the latest AMFI portfolio disclosure. The top 5 positions account for 40.92% of NAV.
What is the largest holding in Nippon India Pharma Fund?
The largest position in Nippon India Pharma Fund is Sun Pharmaceutical Industries Limited, accounting for 13.85% of NAV in the Pharmaceuticals & Biotechnology sector.
Is Nippon India Pharma Fund a concentrated or diversified fund?
With a Gini coefficient of 0.435, Nippon India Pharma Fund is well-diversified. The HHI concentration index is 52,947 bps, which is above the 2500 bps threshold for high concentration. The top 5 holdings together make up 40.92% of the portfolio.
What is the market cap allocation of Nippon India Pharma Fund?
Based on SEBI's AMFI classification, Nippon India Pharma Fund's equity portfolio is split as: Large Cap: 41.14%, Mid Cap: 27.77%, Small Cap: 29.79%. This reflects the fund's positioning within the market cap spectrum.
Which sectors does Nippon India Pharma Fund invest in most?
Nippon India Pharma Fund has the highest allocation to Pharmaceuticals & Biotechnology (73.58%), Healthcare Services (21.34%), Retailing (3.78%). The fund is invested across 3 sectors in total.
How actively managed is Nippon India Pharma Fund compared to other Sectoral / Thematic funds?
Nippon India Pharma Fund has an Active Share of 90.51%, classifying it as "Highly Differentiated" among 237 Sectoral / Thematic peers. This means the fund takes significantly different stock positions compared to its category peers.
What changed in Nippon India Pharma Fund's portfolio in the latest month?
Between 2026-03-31 and 2026-04-30, Nippon India Pharma Fund exited 1 stock (including JB Chemicals & Pharmaceuticals Limited). Total holding count decreased from 38 to 37 stocks.